
Browsing restrictions can be lifted for a fee.
3.07%
Biofrontera inc.
0.05%
Avg of Sector
-0.31%
S&P500

Browsing restrictions can be lifted for a fee.
| Quarterly | EPS Forecast | QoQ | Max | Min |
|---|---|---|---|---|
| 2026Q1 | ||||
| 2026Q2 | ||||
| 2026Q3 | ||||
| 2026Q4 | ||||
| 2027Q1 |
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription cream for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | |||||||
| 2025Q4 | |||||||
| 2025Q3 | |||||||
| 2025Q2 | |||||||
| 2025Q1 |
The most recent financial report for Biofrontera inc. (BFRI) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating BFRI's short-term business performance and financial health. For the latest updates on BFRI's earnings releases, visit this page regularly.
According to the latest financial report, Biofrontera inc. (BFRI) reported an Operating Profit of -6.28M with an Operating Margin of -89.84% this period, representing a decline of 26.57% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
In the latest financial report, Biofrontera inc. (BFRI) announced revenue of 6.99M, with a Year-Over-Year growth rate of -22.46%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
As of the end of the reporting period, Biofrontera inc. (BFRI) had total debt of 4.91M, with a debt ratio of 0.32. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.
At the end of the period, Biofrontera inc. (BFRI) held Total Cash and Cash Equivalents of 3.42M, accounting for 0.22 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
In the latest report, Biofrontera inc. (BFRI) did not achieve the “three margins increasing” benchmark, with a gross margin of 70.7%%, operating margin of -89.84%%, and net margin of -95.1%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess BFRI's profit trajectory and future growth potential.
According to the past four quarterly reports, Biofrontera inc. (BFRI)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.62. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
Biofrontera inc. (BFRI)'s Free Cash Flow (FCF) for the period is -3.82M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 216.39% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.